trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['solid tumor']
just as we all had to become facile with immunotherapy nearly irrespective of the primary sites treated in our solid tumor clinics it's time for most medical oncologists to get familiar with antibody-drug conjugates (adcs) like t-dxd one might even say it's ... destiny #asco22 
Director, GI Oncology, @Intermountain. Interests: neuroendocrine tumors, cancer syndromes, empathy (even had a Whipple myself). Tweets my own.